Venus Pharma gets marketing authorisation nod from France

Company also signed a non-exclusive marketing rights deal with generic drug maker Mylan

Don't want to miss the best from Business Standard?

Venus Pharma GmbH, a subsidiary of Venus Remedies, today said it has got marketing authorisation (MA) approval from France for meropenem, a generic broad spectrum antibiotic injectable.

Besides, it has also signed a non-exclusive marketing rights deal with generic drug maker Mylan to sell meropenem in France.

Ashutosh Jain, Executive Director-cum-Chief Operating Officer (COO), Venus Pharma GmbH, said: "Driven by our MA grants, we are all set to grab the maximum share in the $270-million meropenem market in the EU in the near future."

Meropenem is an off-patented generic broad spectrum anti- bacterial agent of carbapenem family, which fights diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.

"Currently, Venus is generating good revenue from the export of meropenem to EU markets. In fiscal year 2012-2013, we generated a business of about Euro 5 million from meropenem exports. This figure is expected to double by the end of this year.

"We have plans to capture the meropenem share in other lucrative markets as well, including Australia, Spain, Switzerland, South Africa, Malaysia and Gulf Central Committee (GCC) countries where the registration process is in advanced stages," said Dheeraj Aggarwal, Chief Financial Officer (CFO), Venus Remedies.